Updated:
Lanting Capital
LanTing Capital is a cross-border, pharmaceutical-focused strategic consulting and investment firm. It has made 14 investments, including a Series B investment...
Lanting Capital
LanTing Capital is a cross-border, pharmaceutical-focused strategic consulting and investment firm. It has made 14 investments, including a Series B investment in Regor Therapeutics on February 19, 2021. The firm has 2 portfolio exits, with Yunji Technology being its latest exit on October 16, 2025.
General information
Firm type
Venture Capital
Year founded
2017
Location
Region
Asia
Country
China
City
Hangzhou
Corporate office
Hangzhou, Zhejiang, China
Principals
Li Zhubin
Founding Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Lanting Capital?
Founding partner Li Zhubin leads investment decisions. The firm operates with a lean partnership structure typical of early-stage venture managers in China, where the founding partner maintains direct oversight of deal sourcing and portfolio construction.
Which sectors does Lanting Capital focus on?
The firm concentrates on deep-tech verticals — enterprise software, artificial intelligence and machine learning, and semiconductors. These align with China's industrial policy priorities and the Hangzhou-Shanghai corridor's technical talent base.
How does Lanting Capital source its deals?
Lanting relies on a technical founder-referral network and direct outreach to university and corporate R&D labs across China's core innovation hubs. The firm's diligence process mirrors an engineering review, assessing code repositories, semiconductor design tape-outs, and patent filings before committing capital.
Where does Lanting Capital deploy geographically?
Primary deployment runs through China's four largest startup ecosystems — Hangzhou, Shanghai, Shenzhen, and Beijing. Hangzhou serves as the headquarters and anchor, reflecting the firm's proximity to Alibaba's talent ecosystem and Zhejiang University's engineering pipeline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: